APLN and pulmonary arterial hypertension: However, the downregulation of ELA expression in PAH and the beneficial effect of ELA administration on cardiac function and cardiopulmonary remodeling in the MCT rat model of PAH, consistent with that of apelin, supports the potential exploitation of the apelin receptor as a therapeutic target at least in this disease.